Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review
Authors:
Open Access
- 29 December 2022
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 113, 102502
Abstract
No abstract availableKeywords
Funding Information
- Ipsen Biopharmaceuticals Inc
This publication has 77 references indexed in Scilit:
- A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary CancersAmerican Journal of Clinical Oncology, 2018
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trialThe Lancet, 2016
- DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinomaBMC Cancer, 2016
- A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic AdenocarcinomaClinical Cancer Research, 2016
- Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinomaCancer Chemotherapy and Pharmacology, 2015
- Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2015
- Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 TrialJournal of Clinical Oncology, 2014
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic AdenocarcinomaJournal of Immunotherapy, 2010
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008